Feb 15, 2019 8:00 am EST CymaBay Therapeutics Announces Seladelpar Granted Breakthrough Therapy Designation by the FDA for the Treatment of Primary Biliary Cholangitis
Jan 02, 2019 8:00 am EST CymaBay Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
Nov 13, 2018 8:00 am EST CymaBay Therapeutics Presents Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC at The Liver MeetingĀ® 2018
Nov 06, 2018 4:10 pm EST CymaBay Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Oct 30, 2018 4:05 pm EDT CymaBay to Report Third Quarter 2018 Financial Results on Tuesday, November 6
Oct 30, 2018 8:00 am EDT CymaBay Announces the Initiation of the Seladelpar Global Phase 3 Registration Study (ENHANCE) for the Treatment of Primary Biliary Cholangitis and Additional Corporate Updates
Oct 03, 2018 9:00 am EDT CymaBay Therapeutics Announces Additional Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC will be Presented During the Late-Breaking Session at The Liver MeetingĀ®
Sep 24, 2018 8:00 am EDT CymaBay Therapeutics to Participate in Upcoming Investor Conferences in October
Aug 14, 2018 8:00 am EDT CymaBay Therapeutics to Participate in Upcoming Investor Conferences in August and September